Figure 1: EZH2 depletion induces PARPi resistance and genomic stability in BRCA2-deficient tumours. Figure 2: EZH2 loss promotes replication fork protection in BRCA2-deficient tumours through direct ...
In a new study, researchers in Sweden show how the protein EZH2 affects the development of multiple myeloma, and that inhibition of EZH2 could be used as a new strategy to treat the disease. The tumor ...
Triple negative breast cancer (TNBC) is one of the most aggressive and hardest to treat breast cancers, but a new study led by Weill Cornell Medicine suggests a way to stop it from spreading.
The protein EZH2 has long been known as a major driver of prostate cancer because of its ability to inactivate genes that would normally suppress tumor growth. Now, a team at Cedars-Sinai Cancer has ...
Polycomb group protein Ezh2 is an essential epigenetic regulator of embryonic development in mice, but its role in the adult organism is unknown. High expression of Ezh2 in developing murine ...
Researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor ...
Inside the cell, DNA is tightly wrapped around proteins and packed in a complex, 3D structure that we call "chromatin". Chromatin not only protects our genetic material from damage, but also organizes ...
Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas EZH2 is a member of the polycomb group of ...
Prostate cancers are considered immunologically ‘cold’ tumors given the very few patients who respond to checkpoint inhibitor therapy (CPI). Recently, enrichment of interferon stimulated genes (ISGs) ...
Inhibitors of the protein EZH2 are effective against cancers with SMARCB1 mutations such as rhabdoid tumors in children. However, these drugs are subject to treatment resistance. Scientists at St.
This review illustrates the multifaceted roles of EZH2 in non-cancerous diseases, including autoimmunity, fibrosis, metabolic, and neurological disorders. It highlights key pathological events ...
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. Global EZH2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results